Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David N Louis

Showing results (151-160 of 218) with videos related to

Pageof 22
Sort By:
Cancer Cell|December 11, 2024
Epidermal growth factor receptor and Ink4a/Arf: Convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axisRobert M Bachoo, Elizabeth A Maher, Keith L Ligon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2007
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatmentDaniel P Cahill, Kymberly K Levine, Rebecca A Betensky, et al.
Acta Neuropathologica|January 29, 2011
Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytomaGenevieve Schindler, David Capper, Jochen Meyer, et al.
International Journal of Radiation Oncology, Biology, Physics|July 6, 2004
Phase I study pilot arms of radiotherapy and carmustine with temozolomide for anaplastic astrocytoma (Radiation Therapy Oncology Group 9813): implications for studies testing initial treatment of brain tumorsSusan M Chang, Wendy Seiferheld, Walter Curran, et al.
Cell Reports|May 28, 2013
An aberrant transcription factor network essential for Wnt signaling and stem cell maintenance in glioblastomaEsther Rheinbay, Mario L Suvà, Shawn M Gillespie, et al.
Neuro-Oncology|November 30, 2018
Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse gliomaTejus A Bale, Justin T Jordan, Otto Rapalino, et al.
The New England Journal of Medicine|May 1, 2004
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinibThomas J Lynch, Daphne W Bell, Raffaella Sordella, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 12, 2013
Evolutionary etiology of high-grade astrocytomasYurong Song, Qian Zhang, Burak Kutlu, et al.
Neuro-Oncology|August 30, 2024
cIMPACT-NOW update 8: Clarifications on molecular risk parameters and recommendations for WHO grading of meningiomasFelix Sahm, Kenneth D Aldape, Priscilla K Brastianos, et al.
Brain Pathology (Zurich, Switzerland)|August 31, 2025
cIMPACT-NOW update 11: Proposal on adaptation of diagnostic criteria for IDH- and H3-wildtype diffuse high-grade gliomas and for posterior fossa ependymal tumorsPieter Wesseling, David Capper, Guido Reifenberger, et al.
Pageof 22

Showing results (151-160 of 218) with videos related to

Sort By:
Pageof 22
Cancer Cell|December 11, 2024
Epidermal growth factor receptor and Ink4a/Arf: Convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axisRobert M Bachoo, Elizabeth A Maher, Keith L Ligon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2007
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatmentDaniel P Cahill, Kymberly K Levine, Rebecca A Betensky, et al.
Acta Neuropathologica|January 29, 2011
Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytomaGenevieve Schindler, David Capper, Jochen Meyer, et al.
International Journal of Radiation Oncology, Biology, Physics|July 6, 2004
Phase I study pilot arms of radiotherapy and carmustine with temozolomide for anaplastic astrocytoma (Radiation Therapy Oncology Group 9813): implications for studies testing initial treatment of brain tumorsSusan M Chang, Wendy Seiferheld, Walter Curran, et al.
Cell Reports|May 28, 2013
An aberrant transcription factor network essential for Wnt signaling and stem cell maintenance in glioblastomaEsther Rheinbay, Mario L Suvà, Shawn M Gillespie, et al.
Neuro-Oncology|November 30, 2018
Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse gliomaTejus A Bale, Justin T Jordan, Otto Rapalino, et al.
The New England Journal of Medicine|May 1, 2004
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinibThomas J Lynch, Daphne W Bell, Raffaella Sordella, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 12, 2013
Evolutionary etiology of high-grade astrocytomasYurong Song, Qian Zhang, Burak Kutlu, et al.
Neuro-Oncology|August 30, 2024
cIMPACT-NOW update 8: Clarifications on molecular risk parameters and recommendations for WHO grading of meningiomasFelix Sahm, Kenneth D Aldape, Priscilla K Brastianos, et al.
Brain Pathology (Zurich, Switzerland)|August 31, 2025
cIMPACT-NOW update 11: Proposal on adaptation of diagnostic criteria for IDH- and H3-wildtype diffuse high-grade gliomas and for posterior fossa ependymal tumorsPieter Wesseling, David Capper, Guido Reifenberger, et al.
Pageof 22